Navigation Links
Two New Drug Combos May Fight Advanced Breast Cancers
Date:12/8/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Dec. 7 (HealthDay News) -- Breast cancer researchers report they are heartened by the results of two new studies that show combination therapies might improve survival for women with two different types of advanced tumors.

One of the drugs, everolimus (Afinitor), boosted progression-free survival in women with hormone receptor-positive breast cancer but is not yet approved by the U.S. Food and Drug Administration for this indication. The other drug, pertuzumab, improved survival with HER-2 positive tumors, but has not received any FDA approval.

So, the immediate clinical implications are probably "none," said Dr. Jose Baselga, lead author of both studies, which are to be presented at the 2011 San Antonio Breast Cancer Symposium Wednesday and published simultaneously in the New England Journal of Medicine.

In time, though, they could be "practice-changing," said Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center in Boston. "The benefits were very significant."

In the first study, 724 postmenopausal women with hormone receptor-positive breast cancer were randomly assigned to receive the aromatase inhibitor Aromasin (exemestane) plus a placebo or Aromasin plus Afinitor, which is already approved for treatment of kidney cancer.

Women receiving Afinitor lived an average of 7.4 months without a recurrence, versus only 3.2 months in the placebo group.

Half of the women receiving Afinitor showed some kind of tumor response compared to 25 percent in the control group.

"This is one of the most positive studies in hormone receptor-positive breast cancer," said Baselga.

It's not clear yet whether the drug improves overall survival, said the authors of the study, which was funded by Afinitor's maker, Novartis.

The second study involved 808 patients with HER2-positive breast cancer which had already spread to other parts of the body.

HER2-positive breast cancer, which accounts for roughly 20 percent of all breast cancers, is commonly treated with Herceptin (trastuzumab) and chemotherapy. Here, participants were randomly given Herceptin, chemotherapy and a placebo or Herceptin, chemotherapy and pertuzumab.

Women receiving pertuzumab went an average of 18.5 months before experiencing a recurrence compared to 12.4 months in the control group, a 38 percent reduction in risk.

"A six-month improvement is very good," Baselga said.

Herceptin and pertuzumab both block the HER2 growth factor, which causes these types of tumors to proliferate, although the drugs bind to different parts of the HER2 protein. But, pertuzumab goes a step further and suppresses HER2 from binding to HER3 growth factor receptors.

This study was funded by F. Hoffman-La Roche and Genentech, which make pertuzumab.

Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., said the results were "intriguing" and "could potentially be very helpful in patients with two specific subsets of breast cancer."

But he also pointed out that both drugs are very expensive (possibly up to several thousand dollars a month) and are not yet approved for these specific uses.

"As these studies mature, this will be looked at by physicians around country to try to help patients," he said.

More information

The U.S. National Cancer Institute has more on targeted therapies for breast cancer.

SOURCES: Jose Baselga, M.D., Ph.D., chief, hematology/oncology, Massachusetts General Hospital Cancer Center, Boston; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La; Dec. 7, 2011, presentation, San Antonio Breast Cancer Symposium; Dec. 8, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria
2. Losing Weight May Help Fight Gum Disease
3. Discovery may help fight late-stage ovarian cancer
4. Report identifies community health centers as Americas first responders in fighting obesity
5. Current training programs may not prepare firefighters to combat stress
6. Fighting fire with fire: Vampire bacteria has potential as living antibiotic
7. Fighting breast cancer early, one cell at a time
8. Fighting a smarter war against cancer
9. Hockey Fistfights Rarely Cause Injuries, Study Claims
10. More evidence that allergies may help in fighting brain tumors
11. Drug Combo Might Fight Aggressive Breast Cancer More Safely
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two New Drug Combos May Fight Advanced Breast Cancers
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: